VANCOUVER, British Columbia, Sept. 7, 2010 (GLOBE NEWSWIRE) -- biOasis Technologies Inc. (TSX-V:BTI) is pleased to announce that preclinical data on its proprietary Transcend™ (p97) technology for delivery of drugs into the brain was presented during the 13th International Symposium of the Blood-Brain Barrier, held in Zurich, Switzerland from Sept. 2 - 4, 2010.
biOasis' presentation entitled "A new carrier (p97) for delivery of therapeutic compounds beyond the BBB" was given by Dr. Reinhard Gabathuler on Friday, September 3, 2010 in Symposium 6: Vesicular Transport.
ABOUT TRANSCEND™ (p97)
biOasis is developing a proprietary carrier for the transport of therapeutic and imaging agents across the blood brain barrier - Transcend™. Current initiatives within the Transcend™ program include GMP production, preclinical studies and conjugation to a range of small molecule and biologic therapeutics. To address the unmet clinical need to transport drugs across the blood brain barrier biOasis intends to license Transcend™ to multiple corporate partners.
ABOUT INTERNATIONAL SYMPOSIUM OF THE BLOOD-BRAIN BARRIER:
The blood-brain and blood-cerebrospinal fluid barriers (BBB) tightly regulate the exchange of molecules and cells between the circulation and the central nervous system (CNS) and its functional integrity is crucial for neuronal homeostasis: a wide variety of neurological diseases are associated with a deregulated or defective BBB. The aim of this International Meeting is to gather scientists from academia and industry to discuss the latest developments in BBB research and forge new collaborations. Previous meetings have been held with great success in Potsdam (Germany), Cambridge (UK), Muenster (Germany), Szeged (Hungary), Salzburg (Austria), Amsterdam (Netherlands) and London (UK).
The program for the 13th International Symposium encompasses all areas of BBB research and reflects the latest developments in BBB homeostasis, the neurovascular unit, microvascular permeability, intercellular junctions, choroid plexus, pericytes, extracellular matrix, pharmacological targeting of the brain, cell passage across the BBB and also the very latest on in vivo and in vitro BBB models. For more details on this symposium please visit www.physiol.uzh.ch/BBBSymposium.
ABOUT BIOASIS:
biOasis Technologies Inc. is a biopharmaceutical company engaged in the development and commercialization of products for the diagnosis and treatment of neurological diseases and disorders. Its products and technologies are intended for use within the healthcare and life science research markets. The Company is currently developing Cognitest™, a blood test for the diagnosis of Alzheimer's disease. BiOasis is also developing Transcend™, a proprietary molecular carrier intended to transport drugs across the Blood-Brain Barrier for treatment of a wide range of neurological, oncology and infectious disease applications.
Forward Looking Statements
Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: we may not be able to successfully develop and obtain regulatory approval for p97 as a Physician's Aid to Diagnose Alzheimer's, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.
On Behalf of the Board of Directors
Robin Hutchison Director and CEO
"Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release